MBBS MRCP FRCR
Email address: email@example.com
PA/secretary phone number: 020 7830 2396
Fax: 020 7794 3341
Dr Stewart has been a consultant clinical oncologist at Royal Free London since 2012, previously working at University College Hospital London. He is London cancer lead for anal cancer and clinical lead for SIRT. He is clinical oncology college tutor and is developing advanced radiotherapy techniques for GI cancers.
- Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. G. Stewart, I. Chau, A. R. Norman, O. Katopodis, C. Topham, G. Middleton, M. Hill, P. Ross, J. Oates, D. Cunningham. ASCO Meeting Abstracts Jul 15 2004: 3622.
- Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G, Oates JR. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.Br J Cancer. 2004 Oct 18;91(8):1453-8.
- Stewart G, Lee SM. Poor performance status patients with NSCLC and the TOPICAL trial. Lung Cancer in Practice Issue 1.